First look at Sarepta Therapeutics after recent share price moves

Sarepta Therapeutics (SRPT) has been on many investors’ screens after a series of sharp share price moves, including a 3.8% decline in the latest session and a loss of more than 23% in the past 3 months.

At a share price of $16.40, Sarepta Therapeutics has seen a 1 day share price return of 3.76% decline and a 90 day share price return of 23.9% decline. The 1 year total shareholder return of 83.13% decline points to fading momentum and a much weaker overall holder experience.

If this kind of volatility has you looking across biotech and treatment focused names, it could be a good moment to scan our 33 healthcare AI stocks for other ideas backed by a clear data screen.

With the share price under pressure, a value score of 5, an intrinsic value estimate implying a large discount, and analyst targets above the market, you have to ask: is Sarepta undervalued, or is the market already pricing in future growth?

Most Popular Narrative: 19.4% Undervalued

Against Sarepta Therapeutics' last close of $16.40, the most followed narrative points to a fair value of $20.35, leaving a sizeable valuation gap for investors to interpret.

The analysts have a consensus price target of $23.96 for Sarepta Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $80.0, and the most bearish reporting a price target of just $5.0.

Analysts are considering a potential shift from losses to profits, changing margins, and a future earnings multiple that sits well above the broader biotech pack. Curious which assumptions really carry this fair value and how much of the story focuses on Elevidys versus newer programs like siRNA and LGMD gene therapy? The full narrative lays out those moving parts in black and white.

Result: Fair Value of $20.35 (UNDERVALUED)

However, there are still real swing factors here, including Elevidys safety scrutiny after a reported patient death and pressure on exon skipping drugs from ESSENCE data and emerging competitors.

Next Steps

The mixed message here is clear: there are real concerns but also real hopes. Act while the data is fresh and weigh both sides through our 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Sarepta has sharpened your focus, do not stop here; use the Simply Wall St screener to spot other opportunities before they land on everyone else’s radar.

• Target companies the market may have overlooked by running our screener containing 26 high quality undiscovered gems and see which names stand out on quality and fundamentals.
• Prioritise resilience by checking our 68 resilient stocks with low risk scores to find businesses that score well on stability and risk metrics.
• Focus on financial strength through the solid balance sheet and fundamentals stocks screener (42 results) and narrow in on companies with healthier fundamentals backing their share prices.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.